Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer

被引：1
|
作者：
Wyrwicz, L. [1 ]
Oh, D. [2 ]
Weber, P. [3 ]
Bai, Y. [4 ]
Ryu, M. [5 ]
Lee, J. [6 ]
Rivera, F. [7 ]
Alves, G. Vasconcelos [8 ]
Garrido, M. [9 ]
Shiu, K. [10 ]
Fernandez, M. Gonzalez [11 ]
Li, J. [12 ]
Lowery, M. [13 ]
Cil, T. [14 ]
Cruz, F. [15 ]
Qin, S. [16 ]
Yin, L. [17 ]
Bordia, S. [17 ]
Bhagia, P. [17 ]
Rha, S. [18 ]
机构：
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Univ La Frontera, James Lind Canc Res Ctr, Temuco, Chile
[4] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[5] Univ Ulsan, Asan Med Ctr, Coll Med, Songpa Gu, Seoul, South Korea
[6] Samsung Med Ctr, Seoul, South Korea
[7] Univ Hosp Marques Valdecilla, IDIVAL, Santander, Spain
[8] Hosp Nossa Senhora Coinceicao, Porto Alegre, RS, Brazil
[9] Pontificia Univ Catolica Chile, Santiago, Chile
[10] Univ Coll London NHS Fdn Trust, London, England
[11] IMAT Oncomed, Monteria, Colombia
[12] Tongji Univ, Shanghai East Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[13] Trin St James Canc Inst, Dublin, Ireland
[14] Hlth & Sci Univ, Adana City Hosp, Adana, Turkiye
[15] Nucleo Pesquisa Ensino, Rede Sao Camilo, Sao Paulo, Brazil
[16] Gen Hosp Eastern Theater PLA, Canc Ctr, Nanjing, Peoples R China
[17] Merck Co Inc, Rahway, NJ USA
[18] Yonsei Univ, Yonsei Univ Hlth Syst, Songdang Inst Canc Res, Yonsei Canc Ctr,Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-3
引用
收藏
页码：S181 / S181
页数：1
相关论文
共 50 条
  • [21] Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.
    Janjigian, Yelena Y.
    Kawazoe, Akihito
    Yanez, Patricio Eduardo
    Luo, Suxia
    Lonardi, Sara
    Kolesnik, Oleksii
    Barajas, Olga
    Bai, Yuxian
    Shen, Lin
    Tang, Yong
    Wyrwicz, Lucjan
    Shitara, Kohei
    Qin, Shukui
    Van Cutsem, Eric
    Tabernero, Josep
    Li, Lie
    Shih, Chie-Schin
    Bhagia, Pooja
    Chung, Hyun Cheol Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Phase III KEYNOTE-585 study of chemotherapy (Chemo) plus pembrolizumab (Pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
    Bang, Y-J.
    Van Cutsem, E.
    Fuchs, C. S.
    Ohtsu, A.
    Tabernero, J.
    Ilson, D. H.
    Hyung, W. J.
    Strong, V. E.
    Goetze, T. O.
    Yoshikawa, T.
    Tang, L. H.
    Hwang, P. M. T.
    Adelberg, D.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 268 - 268
  • [24] Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    Wu, Haijun
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [25] Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
    Satake, Hironaga
    Lee, Keun-Wook
    Chung, Hyun Cheol
    Lee, Jeeyun
    Yamaguchi, Kensei
    Chen, Jen-Shi
    Yoshikawa, Takaki
    Amagai, Kenji
    Yeh, Kun-Huei
    Goto, Masahiro
    Chao, Yee
    Lam, Ka-On
    Han, Shi Rong
    Shiratori, Shinichi
    Shah, Sukrut
    Shitara, Kohei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (03) : 221 - 229
  • [26] KEYNOTE-585: Phase 3 study of chemotherapy (chemo) plus pembrolizumab (pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Ilson, David H.
    Hyung, Woo Jin
    Strong, Vivian E.
    Goetze, Thorsten Oliver
    Yoshikawa, Takaki
    Tang, Laura H.
    Hwang, Peggy May Tan
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study
    Chalabi, M.
    Verschoor, Y. L.
    Van De Haar, J.
    van den Berg, J.
    Kodach, L.
    van Sandick, J.
    van Dieren, J.
    Balduzzi, S.
    Grootscholten, M. C.
    Veenhof, X.
    Hartemink, K.
    Vollebergh, M.
    Owers, E.
    Bartels-Rutten, A.
    den Hartog-Lievaart, P.
    van Leerdam, M.
    Schumacher, T. N.
    Haanen, J. B. A. G.
    Voest, E. E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1106 - S1106
  • [28] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [29] Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
    Tabernero, J.
    Van Cussem, E.
    Bang, Y.
    Fuchs, C.
    Wyrwicz, L.
    Lee, K.
    Kudaba, I.
    Garrido, M.
    Chung, C.
    Salguero, C. Castro
    Mansoor, W.
    Braghiroli, M.
    Goekkurt, E.
    Chao, J.
    Wainberg, Z.
    Kher, U.
    Shah, S.
    Karg, S.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 152 - +
  • [30] Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer
    Janjigian, Y.
    Kawazoe, A.
    Weber, P.
    Luo, S.
    Lonardi, S.
    Kolesnik, O.
    Barajas, O.
    Bai, Y.
    Shen, L.
    Tang, Y.
    Wyrwicz, L.
    Shitara, K.
    Qin, S.
    Van Cutsem, E.
    Tabernero, J.
    Li, L.
    Shih, C.
    Bhagia, P.
    Chung, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S227 - S227
12345